London, UK, 22 January 2006: BTG plc (LSE: BGC), the medical innovations company, today announces the successful outcome of a Phase I/II study of plevitrexed, a selective inhibitor of thymidylate synthase targeting gastric, pancreatic and ovarian cancer. The study, presented at the ASCO 2007 Gastrointestinal Cancers Symposium 1 in Orlando, Florida on 19 January, was designed to investigate the efficacy, safety and tolerability of plevitrexed in patients with advanced and/or metastatic gastric cancer.
